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Summary
 
2B4 is a cell surface glycoprotein related to CD2 and implicated in the regulation of natural
killer and T lymphocyte function. A recombinant protein containing the extracellular region of
mouse (m)2B4 attached to avidin-coated fluorescent beads bound to rodent cells, and binding
was completely blocked by CD48 monoclonal antibodies (mAbs). Using surface plasmon reso-
nance, we showed that purified soluble mCD48 bound m2B4 with a six- to ninefold higher af-
 
finity (
 
K
 
d 
 
< 
 
16 
 
m
 
M at 37
 
8
 
C) than its other ligand, CD2. Human CD48 bound human 2B4
with a similar affinity (
 
K
 
d 
 
< 
 
8 
 
m
 
M). The finding of an additional ligand for CD48 provides an
explanation for distinct functional effects observed on perturbing CD2 and CD48 with mAbs
or by genetic manipulation.
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T
 
he majority of leukocyte surface proteins can be
grouped according to the type of domain they contain
(1). The immunoglobulin superfamily (IgSF)
 
1
 
 domain is
the most highly represented domain type, found in 34% of
leukocyte surface proteins. Of these, 45% have extracellular
regions comprised of two IgSF domains in tandem, an ar-
rangement that appears to be particularly favored for cell–
cell recognition molecules, including the TCR. Other
two-IgSF-domain leukocyte surface antigens known to
mediate cell–cell interactions include CD2, CD58, CD48,
CD80, CD86, CD102 (1), and OX2 (2). Among these,
CD2 and its ligands, CD58 in humans (3, 4) and CD48 in
rodents (5, 6) belong to the CD2 subset of the IgSF, which
also includes 2B4, CDw150, CD84, and Ly-9 (Fig. 1), all
of which are expressed on hematopoietic cells (1, 7, 8).
With the exception of Ly-9, the extracellular regions of all
of these molecules contain a membrane distal IgSF V-set
domain and a membrane proximal C2-set domain (Fig. 1 
 
A
 
).
In Ly-9, this arrangement is duplicated to give four IgSF
domains. The related sequence and chromosomal location
of this subset together with interactions among members
suggest they evolved from one molecule which mediated
homophilic recognition (1, 9).
The 2B4 antigen was identified as an antigen on NK
cells and T cells capable of non-MHC–restricted killing
(10). 2B4 is also expressed on murine dendritic epidermal
 
g
 
/
 
d
 
 T cells (DETCs [11, 12]). A correlation in DETCs be-
tween 2B4 expression and capacity to lyse transformed ker-
atinocytes suggests a role for 2B4 in killing skin tumors
(11). Evidence for a role in regulation of NK and T cell ac-
tivity by 2B4 is provided by the cross-linking effects of the
2B4 mAb, which enhances lytic function of 2B4-express-
ing cells, suggesting that 2B4 can transduce stimulatory sig-
nals (10, 12). Costimulation experiments with CD3 and
2B4 mAbs suggest 2B4, like CD2 (7), can enhance signals
through the TCR (12). However, the mechanisms by
which 2B4 and CD2 regulate cell activation are presum-
ably different, as there are marked differences in their cyto-
plasmic regions. For example, the 2B4 cytoplasmic region
contains tyrosine motifs that are potential targets for phos-
phorylation (13), whereas the CD2 cytoplasmic region
contains proline-rich motifs and no tyrosine residues (14).
Since CD2 binds to CD58 and CD48, it seemed reason-
able to predict that 2B4 would also bind another molecule
within the CD2 subfamily. Interactions between leukocyte
 
1
 
Abbreviations used in this paper:
 
 CD4d3
 
1
 
4, domains 3 and 4 of rat CD4;
CD4L, rat CD4 leader; h, human; IgSF, immunoglobulin superfamily;
m, mouse; r, rat; RU, response unit(s).
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cell surface molecules are weak and transient, often making
them difficult to identify (15). For use as ligand-binding
tools, recombinant forms of extracellular regions must be
made sufficiently multivalent to achieve the necessary avidity
to bind to cells. In a modification of a previously described
assay (16), an enzymatically biotinylated peptide (17, 18)
engineered onto CD4d3
 
1
 
4 (domains 3 and 4 of rat CD4)
fusion proteins was used to attach the recombinant molecules
in an oriented manner to fluorescent beads. We used this
assay to explore the ligand-binding properties of 2B4, and
discovered it is a ligand for CD48 in rodents and humans.
 
Materials and Methods
 
mAbs.
 
mAbs used were 2B4 (10); rat (r)CD4d3
 
1
 
4 mAb,
OX68; mouse (m)CD2 mAb, RM2.1 (19); mCD48 mAb,
OX78; rCD48 mAb, OX45; and rCD147 mAb, OX47. The OX
mAbs are all referenced in the European Collection of Animal
Cell Cultures (Porton Down, Wiltshire, UK). Purified HM48-1
(hamster anti–mouse CD48 [5]) was provided by Dr. H. Yagita
(Juntendo University School of Medicine, Tokyo, Japan), and
control 2C11 (hamster anti–mouse CD3) by Dr. E. Adams (Sir
William Dunn School of Pathology). Human (h)CD48 mAbs
were MEM 102 (20) and 6.28 (21), provided by Drs. V. Horejsi
(Institute of Molecular Genetics, Prague, Czech Republic) and
D. Thorley-Lawson (Department of Pathology, Tufts University,
Boston, MA), respectively.
 
Vector Construction for Recombinant Proteins.
 
The constructs for
CD4d3
 
1
 
4 chimeric proteins used previously (22) were modified
to contain at the COOH terminus a consensus peptide sequence
recognized by the 
 
Escherichia coli
 
 biotin holoenzyme synthetase,
BirA (17, 18). DNA encoding the amino acid sequence NSGSL-
HHILDAQKMVWNHR* was amplified by PCR using 5
 
9
 
(agggttgaattccggatcactgcatcatattctgg) and 3
 
9
 
 (ctactaggatccttaacgat-
gattccacacc) oligonucleotides (restriction enzyme sites are under-
lined) and an HLA A2 construct as template (17), provided by
Dr. Paul Moss (Institute of Molecular Medicine, Oxford, UK).
This fragment was inserted via a 5
 
9
 
 EcoRI site and a 3
 
9
 
 BamHI
site into a modified Bluescript (BS KS
 
1
 
) vector containing a
rat CD4 leader and rat CD4d3
 
1
 
4 (CD4Ld3
 
1
 
4RI [23]). An
XbaI-BamHI fragment encoding XbaI-CD4L-SalI-CD4d3
 
1
 
4-
EcoRI-biotin peptide-stop-BamHI was transferred to a modified
pEF-BOS vector (24), pEF-BOS-XB. To construct fusion pro-
teins, the XbaI-SalI fragment encoding CD4L was replaced with
DNA encoding the extracellular region of m2B4 or h2B4 ampli-
fied from plasmid DNA (13; Boles, K., and P.A. Mathew, manu-
script in preparation) or domains 1–3 of rCD5 (25). XbaI sites
were introduced 42 bases (m2B4) and 52 bases (h2B4) upstream
of the initiation Met. The join at the SalI (g tcg acc) junction
with rCD4d3 was m2B4:VPSNFRST (the residues containing
the SalI site are underlined) and at the homologous region for
h2B4. Confirmatory sequence analysis of all constructs (model
373A DNA sequencing system; Applied Biosystems, Inc., Foster
City, CA) revealed for m2B4-CD4d3
 
1
 
4 a 3-base deletion, the
correct sequence reading at base 619: gctttgtac encoding ALY in
the C strand of domain 2. To construct soluble His-tagged
hCD48, DNA (sequence data available from EMBL/GenBank/
DDBJ under accession no. M37766) encoding the extracellular
region with an XbaI site 13 bases upstream of the initiation Met
and a His-tag:TLARSTHHHHHH* contained in the 3
 
9
 
 oligonu-
cleotide (ccactaggatcctaatgatggtggtgatgatgggtcgaccgggccagggtacaggg-
tggactgag) was amplified by PCR from mouse macrophage cDNA
(provided by Dr. J. Mahoney, Sir William Dunn School of Pathol-
ogy) and cloned into pEF-BOS-XB.
 
Expression of Recombinant Biotinylated Chimeric Proteins.
 
Recom-
binant proteins were expressed by transfection of 293T cells with
40 
 
m
 
g plasmid DNA/5 
 
3 
 
10
 
6 
 
cells/175-cm
 
2 
 
flask using calcium
phosphate. After removal of precipitate at 16 h, cells were incu-
bated for 48 h in 7.5–10 ml X-Vivo-10 serum-free medium
(BioWhittaker, Walkersville, MD). Levels of four Ig domain fu-
sion proteins as assayed in a CD4d3
 
1
 
4 inhibition ELISA (22)
were routinely in the region of 50–150 
 
m
 
g/175-cm
 
2 
 
flask. To en-
zymatically biotinylate CD4d3
 
1
 
4 fusion proteins, supernatant was
exchanged (
 
z
 
1:20) into 10 mM Tris-HCl, pH 8, and concentrated
to 0.5–0.8 ml using a 10,000 mol wt cutoff 15-ml centricon (Ami-
con, Inc., Beverly, MA) and incubated with 1 
 
m
 
l BIR enzyme
(Avidity, Denver, CO). Biotinylation was complete after 2–4 h at
30
 
8
 
C or overnight incubation at room temperature as assessed by
binding of streptavidin to chimeras immobilized via a CD4d3
 
1
 
4
mAb in a BIAcore
 
Ô
 
 (reference 26, and see below). Excess biotin
was removed by dialysis (twice with 800 ml PBS for 20 h), and
biotinylated material was aliquoted and stored at 
 
2
 
20
 
8
 
C.
 
Expression of His-tagged Recombinant Proteins.
 
Purified mono-
meric mCD48 containing a COOH-terminal His-tag was pre-
pared as described (27). Soluble hCD48 was expressed as for
CD4d3
 
1
 
4 fusion proteins in DMEM containing 10% FCS. Solu-
ble hCD48 was purified using an FPLC (Pharmacia Biotech Ltd.,
St. Albans, UK) first on a 1-ml HiTrap
 
Ò
 
 column (Pharmacia Bio-
tech Ltd.). Monomeric soluble hCD48 was then eluted in 0.1-ml
fractions from Superdex 75 (Pharmacia Biotech Ltd.) and used
within 4 h. Concentration was measured at 280 nm using an ex-
tinction coefficient of 1.6 cm
 
2
 
/mg (28), and purity was checked
by SDS-PAGE. Purified hCD48 was shown to be antigenically
active by binding stoichiometric amounts of the 6.28 mAb when
immobilized via the His-tag on an NTA chip (Biacore AB, Upp-
sala, Sweden). In experiments with h2B4-CD4d3
 
1
 
4 and control
CD4d3
 
1
 
4 immobilized on streptavidin-coated beads (Dynal
A.S., Oslo, Norway), 
 
.
 
70% hCD48 could be depleted as assessed
by SDS-PAGE and densitometry.
 
Cell-binding Experiments.
 
Experimental procedures were es-
sentially as described (16). Biotinylated proteins (1–2 
 
m
 
g/sample)
were mixed with 10–20 
 
m
 
l avidin-coated fluorescent beads/sam-
ple (VFP-0552-5; Spherotech, Inc., Libertyville, IL). Small vol-
umes were shaken in round-bottomed microtiter plates. Where
volume adjustment was necessary, beads were centrifuged and re-
suspended in PBS containing 0.2% BSA (PBS/BSA). For coating
beads with mAbs in blocking studies, beads were washed twice in
PBS/BSA and resuspended in PBS/BSA containing 2B4 or
OX68 mAb (1 
 
m
 
g/20 
 
m
 
l beads).
 
BIAcore
 
Ô
 
 Analysis of Affinity and Kinetics of the 2B4–CD48 In-
teraction.
 
Experiments were carried out on a BIAcore
 
Ô
 
 2000
(Biacore AB) using HBS buffer (25 mM Hepes, pH 7.4, 150 mM
NaCl, 3.4 mM EDTA, and 0.005% surfactant P20) supplied by
the manufacturer. Streptavidin 0.2 mg/ml (Pierce Chemical Co.,
Rockford, IL) was coupled in 10 mM sodium acetate, pH 5, to a
research grade CM5 chip (Biacore AB) using an amine coupling
kit (Biacore AB) using an activation time of 5 min, resulting in
immobilization of 
 
z
 
2,000–3,000 response units (RU). Soluble
mCD2 comprising the extracellular region of mCD2 (27) at 90
 
m
 
g/ml was coupled similarly with an activation time of 1.8 min.
The surface of the chip was washed with 0.1 M glycine-HCl, pH
2.5, after coupling. Biotinylated 2B4-CD4d3
 
1
 
4 and control
rCD5-CD4d3
 
1
 
4 or CD4d3
 
1
 
4 were then injected over immo-
bilized streptavidin. Equilibrium affinity measurements were per- 
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formed as described (26). Increasing and decreasing concentra-
tions of mCD48 (5-
 
m
 
l injections at 20 
 
m
 
l/min) were passed over
m2B4-CD4d3
 
1
 
4, rCD5-CD4d3
 
1
 
4, and mCD2. Kinetic mea-
surements were made at 37
 
°
 
C (28). mCD48 (23.4 
 
m
 
M) was in-
jected for 3 s at 100 
 
m
 
l/min over high and low levels of m2B4-
CD4d3
 
1
 
4, rCD5-CD4d3
 
1
 
4, and mCD2. Similarly, to measure
affinity, hCD48 was passed over h2B4-CD4d3
 
1
 
4 and CD4d3
 
1
 
4,
and for kinetics, hCD48 (14.4 
 
m
 
M) was passed over high and low
levels of h2B4-CD4d3
 
1
 
4 and CD4d3
 
1
 
4. Dissociation rates
were measured for mCD48 as described (28) using Origin soft-
ware, version 5.0 (Microcal Software, Inc., Northampton, MA).
The effect of 2B4 mAb on mCD48 (23.4 
 
m
 
M) binding was tested
by first passing 2B4 mAb at 10 
 
m
 
g/ml at 5 
 
m
 
l/min over m2B4-
CD4d3
 
1
 
4 until saturation was reached.
 
Results
 
m2B4 Binds to CD48.
 
A binding reagent for a m2B4
ligand was constructed by expressing the two IgSF domains
of 2B4 as a recombinant chimeric protein with domains 3
and 4 of rCD4 (m2B4-CD4d3
 
1
 
4; Fig. 1 
 
B
 
). The recombi-
nant protein differed from previously described CD4d3
 
1
 
4
chimeras (22) in that it contained a peptide sequence at its
COOH terminus that can be specifically biotinylated by
the 
 
E. coli
 
 enzyme, BirA (18). The expressed protein was
biotinylated by the BirA enzyme in vitro and tested for re-
activity with streptavidin and 2B4 mAb by surface plasmon
resonance (not shown). The in vitro biotinylation of the
recombinant protein simplified the previously described
method (16) for detecting low-affinity interactions at the
cell surface by enabling the biotinylated m2B4-CD4d3
 
1
 
4
to be directly immobilized on avidin-coated beads (Fig. 1 
 
C
 
)
without the use of a CD4d3
 
1
 
4 mAb. The assay was shown
to be at least as sensitive as coupling CD4d3
 
1
 
4 fusion pro-
teins to beads using a CD4d3
 
1
 
4 mAb (data not shown).
m2B4-CD4d3
 
1
 
4 beads bound to LPS and Con A–acti-
vated mouse spleen cells (Fig. 2, 
 
A
 
 and 
 
B
 
). The broad dis-
tribution of the ligand and our own expectation that it
might be another member of the CD2 subset suggested
CD48 as a likely candidate. In support of this, the binding
of m2B4-CD4d3
 
1
 
4 beads was blocked by the CD48
mAb, OX78, but not by a control CD2 mAb (Fig. 2, 
 
A
 
and 
 
B). A second CD48 mAb, HM48-1, which blocks the
CD2–CD48 interaction (5) and is known to have func-
tional effects in vivo (29, 30), also inhibited the binding of
m2B4-CD4d314 beads (Fig. 2 C).
Preincubation of m2B4-CD4d314 beads with 2B4 mAb
before presentation to cells partially inhibited binding,
whereas a control CD4d314 mAb had no effect (Fig. 2 D).
The partial inhibition suggests that sites recognized by 2B4
mAb and CD48 may be close but do not overlap.
The m2B4-CD4d314 beads also bound to rat thy-
mocytes (not shown) and a rat mast cell line (Fig. 2 E).
This binding was completely inhibited by a rat CD48 mAb
Figure 1. CD2 IgSF subfamily. (A) Schematic representation of mouse
CD2, CD48, 2B4, and Ly-9 and human CD58, CDw150 (SLAM), and
CD84. (B) Recombinant chimeric m2B4-CD4d314 protein. (C) The
2B4-CD4d314 fluorescent beads used for ligand identification.
Figure 2. m2B4-CD4d314
fluorescent beads bind to rodent
CD48 on cells. m2B4-CD4d
314 fluorescent beads bind to
LPS (A and D) and Con A (B)–
activated and resting (C) mouse
spleen cells and a rat basophilic
leukemia cell line (E). Preincu-
bation of cells with mCD48
mAbs OX78 (A and B) or
HM48-1 (C) or rCD48 mAb
(E) blocked binding to the level
seen with the negative control,
rCD5-CD4d314. Control mCD2 mAb (A and B), mCD3 mAb 2C11
(C), or rCD147 mAb (E) did not block binding. Preincubation of m2B4-
CD4d314 fluorescent beads with 2B4 mAb but not a CD4d314 mAb
partially blocks binding to cells (D).2086 2B4 Is a Ligand for CD48
(Fig. 2 E), indicating that the 2B4–CD48 interaction is
conserved between these species, as is the CD2–CD48 in-
teraction (27).
h2B4 Binds to CD48. The finding that rodent 2B4 and
CD48 bind to each other suggests that 2B4 may be a ligand
for CD48 in humans. The recent isolation of h2B4 cDNA
(Boles, K., and P.A. Mathew, manuscript in preparation)
made it possible to test this hypothesis. An h2B4 rCD4d314
fusion protein with a COOH-terminal biotinylation tag
(h2B4-CD4d314) was expressed at levels similar to those
obtained with the m2B4-CD4d314 construct, consistent
with it being correctly folded. Biotinylated h2B4-CD4d314
immobilized on fluorescent beads bound to PBMCs (Fig. 3
A). Two hCD48 mAbs (6.28 and MEM 102) were tested for
blocking effects on h2B4-CD4d314 cell binding. Preincu-
bation of cells with the mAbs revealed blocking of h2B4-
CD4d314 binding by 6.28 mAb but not by MEM 102
mAb (Fig. 3 A). Both 6.28 and MEM 102 mAbs bound to
the cells, with the IgG3 6.28 mAb giving a lower signal as
detected by the FITC-labeled secondary reagent (Fig. 3 B).
The specificity of blocking by a CD48 mAb against a partic-
ular epitope provides convincing evidence that antigenically
active h2B4 is binding to CD48 at the cell surface.
Affinity and Kinetic Analysis of the 2B4–CD48 Interaction.
The finding that mCD48 has two ligands, 2B4 and CD2,
raises the question of which interaction dominates in a par-
ticular response. This will depend on the distribution and
level of expression of the proteins and the affinities of the
two interactions. The latter was investigated by analysis on
a BIAcoreÔ, which permits protein interactions to be fol-
lowed in real time using a detection system based on
Figure 3. h2B4-CD4d314 fluorescent beads bind to hCD48 on cells.
(A) h2B4-CD4d314 fluorescent beads bind to PBMCs. Preincubation of
cells with hCD48 mAb 6.28 but not MEM 102 blocked binding to the
level seen with the negative control, rCD4d314. (B) CD48 mAbs 6.28
and MEM 102 bind to the cells in A as detected with a fluorescent-
labeled second mAb.
Figure 4. Affinity and dissociation rate of soluble mCD48 binding to
m2B4-CD4d314. (A) Soluble mCD48 was injected at the indicated con-
centration through flow cells with immobilized m2B4-CD4d314 (3,733
RU) or as a negative control, rCD5-CD4d314 (1,857 RU), at 378C. (B)
The difference between the response at equilibrium in the m2B4-
CD4d314 and control flow cells is plotted against the mCD48 concen-
tration. A Kd 5 15 mM and maximum binding of 1,197–1,225 RU were
calculated by nonlinear curve fitting of the Langmuir binding isotherm
(line) to data (circles) from A with negative control subtracted. (C) Scat-
chard plot of data in B plus data for mCD48 binding mCD2. (D) Soluble
mCD48 (23.4 mM) was injected over immobilized m2B4-CD4d314 at
high (1,060 RU) and low (572 RU) levels, mCD2 (557 RU), and rCD5-
CD4d314 (1,083 RU). A koff 5 3 s21 for 2B4, 22 s21 for mCD2, and 41
s21 for rCD5-CD4d314 was calculated by exponential decay curve fit-
ting (line) to dissociation data (symbols). (E) In the experiment shown in
D, soluble mCD48 (23.4 mM) was injected over immobilized m2B4-
CD4d314 (1,060 RU) before and after saturation with 2B4 mAb.2087 Brown et al.
surface plasmon resonance. The affinity was measured by
determining the level of binding at equilibrium after injec-
tion of a range of concentrations of mCD48 over immobi-
lized m2B4-CD4d314 and mCD2. Immobilized rCD5-
CD4d314 was used as a negative control in the reference
flow cell. A representative experiment with increasing con-
centrations of mCD48 injected at 378C is shown in Fig. 4 A.
The difference between the response at equilibrium in the
m2B4 and control flow cells represents binding (Fig. 4 B). A
Scatchard transformation of the data is shown in Fig. 4 C.
mCD48 bound to m2B4 with a Kd < 16 mM at 378C (Fig.
4, B and C, and Table 1). This was significantly higher than
the mCD48–mCD2 interaction (Kd < 90 mM) measured si-
multaneously (Fig. 4 C, and Table 1). Values determined for
the mCD48–mCD2 interaction agree with published data
(27; Table 1). At 258C, mCD48 bound m2B4 and mCD2
with a Kd of 7 and 49 mM, respectively (data not shown).
Kinetic studies were carried out at 378C to determine
the dissociation rate constant (koff) of the mCD48–m2B4
interaction. mCD48 dissociated more slowly from m2B4
(koff 5 3 s21) than from mCD2 (koff .20 s21) (Fig. 4 D).
The koff was the same when the level of immobilized m2B4-
CD4d314 was decreased, indicating that the dissociation
rate measured was not affected by rebinding or mass trans-
port limitations. This suggests that the higher affinity of the
2B4–CD48 interaction is the result of a decreased koff.
The partial blocking effect of 2B4 mAb on cell binding (Fig.
2 D) was reproduced in BIAcoreÔ analysis as shown in Fig.
4 E. Saturation of m2B4-CD4d314 with 2B4 mAb before
injection of mCD48 reduced the level of mCD48 binding.
To measure the affinity of the interaction between h2B4
and hCD48, a soluble form of hCD48 was produced. In
analyses similar to that carried out for the m2B4–mCD48
interaction, affinity measurements were made with soluble
hCD48 and immobilized h2B4-CD4d314. Both nonlinear
curve fitting (Fig. 5 B) and linear regression analysis of the
Scatchard plot (Fig. 5 C) yielded a Kd < 8 mM (Table 1).
The apparent koff was 5 and 7 s21 when measured with high
and low levels of immobilized h2B4 (Fig. 5 D). This indi-
cates that dissociation is limited by mass transport and/or
rebinding and that the true koff is $7 s21.
Discussion
The interaction between 2B4 and CD48 identified in this
study represents a new ligand pair that is conserved between
rodents and humans within the CD2 subset of IgSF mole-
cules. A previous study failed to demonstrate an additional
ligand for CD48 in the rat (16). However, 2B4 is expressed
on a limited range of cell types, and these were not examined
(16). Interestingly, in preliminary experiments, the binding
of biotinylated multivalent CD48-CD4d314 to lympho-
kine-activated killer (LAK) cells shown to express both 2B4
and CD2 was entirely blocked by a CD2 mAb (Brown,
M.H., unpublished observations). It is possible that with the
particular conditions used to generate the LAK cells, too few
expressed 2B4 at a sufficiently high surface density and/or
2B4 has insufficient lateral mobility to support multivalent
binding. Limitations of this type of assay have been demon-
strated previously (16). Thus, our observation that CD48
mAbs completely block 2B4-CD4d314 binding to cells
does not rule out the existence of another ligand for 2B4.
Ianelli et al. have reported that an hCD48–IgM fusion pro-
tein binds to epithelial cells, which do not express CD2 (31).
It is unclear whether 2B4 is the CD48 ligand on these cells.
Table 1. Comparison of Affinity and Dissociation Rates for Soluble 
CD48 Binding to Immobilized 2B4 and CD2 at 37°C
Immobilized Soluble Kd koff
mMs 21
m2B4 mCD48 16 3
h2B4 hCD48 8 .7
mCD2 mCD48 90* .10*
hCD2 hCD58 9–22‡ .4‡
*Data from reference 27.
‡Data from reference 28.
Figure 5. Affinity and dissociation
rate of soluble hCD48 binding to
h2B4-CD4d314. (A) Soluble hCD48
was injected at the indicated concen-
tration through flow cells with immo-
bilized h2B4-CD4d314 (2,166 RU)
or as a negative control, CD4d314
(2,112 RU), at 378C. (B) The differ-
ence between the response at equilib-
rium in the h2B4-CD4d314 and
control flow cells is plotted against the
hCD48 concentration. A Kd 5 8 mM
and maximum binding of 945–959 RU were calculated by nonlinear curve
fitting of the Langmuir binding isotherm (line) to data (circles) from A with
negative control subtracted. (C) Scatchard plot of data in B. (D) Soluble
hCD48 (14.4 mM) was injected over immobilized h2B4-CD4d314 at high
(1,073 RU) and low levels (578 RU), and CD4d314 (1,782 RU). A koff 5
5 s21 for 2B4 high, 7 s21 for h2B4 low, and 41 s21 for CD4d314 was calcu-
lated by exponential decay curve fitting (line) to dissociation data (symbols).2088 2B4 Is a Ligand for CD48
Our finding that the m2B4–mCD48 interaction in the
mouse has a significantly higher affinity than the mouse or
rat CD2–CD48 interactions (26, 27; Table 1) suggests that
it is biologically significant. Moreover, the strength of the
2B4–CD48 interaction is conserved across species, with
similar affinities being observed for the mouse and human
2B4–CD48 interactions (Table 1). Although fast, the 2B4–
CD48 dissociation rate constants are comparable with val-
ues measured for other cell–cell recognition molecules, in-
cluding the CD2–CD48 and CD2–CD58 interactions (27,
28). An interaction has been reported between hCD48 and
hCD2 (32, 33), but this appears to be exceptionally weak
(Kd .0.5 mM [28]). Since CD2 binds with a much higher
affinity to CD58 and essentially all cells that express CD48
also express CD58, it is doubtful that the CD2–CD48 in-
teraction is of physiological significance in humans. In con-
trast, the relatively high affinity of h2B4 for hCD48 sug-
gests that this latter interaction is physiologically important.
The same CD48 mAbs block CD2 and 2B4 binding to
CD48, suggesting that the 2B4 ligand binding site, like the
CD2 binding site (34), lies on the GFCC9C99 face of the V
domain. Thus, a similar topology for the CD2–CD48 and
2B4–CD48 complexes can be predicted. The dimensions of
the CD2–CD48 complex are predicted to be similar to the
dimensions of the TCR–MHC complex (14 nm from mem-
brane to membrane [7]). This has led to the suggestion that
the maintenance of this intercellular distance is important for
initiation of TCR–peptide MHC ligation (7). Interestingly,
structure determination of an NK killer inhibitory receptor
(KIR [35]) predicts that when bound to MHC class I, the
complex will also span a similar distance. Together with
functional studies (for a review, see reference 36), this sug-
gests that CD2 on NK cells may contribute to activation
through NK receptors. This hypothesis is supported by stud-
ies with mAbs and CD58-transfected cells that suggest that
CD2 ligation can enhance activation of NK cells (36, 37). By
analogy with CD2 (7) and substantiated by experiments with
2B4 mAb (10, 12), the 2B4–CD48 interaction may enhance
NK and TCR ligand interaction as well as contributing to
signals initiated through NK receptors and the TCR.
The expression on the same lymphocytes of two proteins
(2B4 and CD2) that bind the same ligand (CD48) raises the
question of whether CD2 and 2B4 have distinct functions.
An analogy is exemplified by the well-characterized inter-
actions of the T cell molecules CD28 and CD152, which
bind the same ligands, CD80 and CD86 (38). There are sev-
eral interesting parallels that can be drawn between these two
pairs of molecules (CD28/CD152 and 2B4/CD2) that share
ligands. First, they have different affinities for the same
ligand, i.e., 2B4 and CD2 have different affinities for CD48,
and CD152 has a 10-fold higher affinity than CD28 for
CD80 (39). Second, their patterns of expression differ. The
expression of both 2B4 and CD152 is much enhanced on
activated cells (10, 11, 38), whereas both CD2 and CD28 are
present on resting and activated cells. Third, they have dif-
ferent cytoplasmic regions. In the case of CD28 and CD152,
this results in completely different functions, with CD28
stimulating and CD152 inhibiting (38). Thus, it seems likely
that the cytoplasmic portions of 2B4 and CD2 will confer
different functions. The more restricted expression of 2B4
on cells associated with non-MHC–restricted killing com-
pared with CD2, which is present on virtually all T cells,
suggests the primary role of 2B4 may be in generation of
lytic activity. This is supported by the absence of effects of
CD48 mAbs on target recognition (29).
Experiments have been done in vitro and in vivo with
CD48 and CD2 mAbs that can now be reinterpreted in the
light of there being two ligands for mCD48. For example,
a CD48 mAb (HM48-1) has been shown to inhibit devel-
opment of non-MHC–restricted lytic activity, whereas a
blocking CD2 mAb had no effect (29). One explanation
for this is that it is the 2B4–CD48 and not the CD2–CD48
interaction that has a major role in the development of the
lytic population. In vivo, the synergistic effects of blocking
CD2 and CD48 mAbs on allograft survival may be ex-
plained by disruption of the 2B4–CD48 and the CD2–
CD48 interactions (30). Clearly, further experiments are
needed to clarify this point. The activating properties (10)
and partial inhibition of the 2B4–CD48 interaction make
the currently available 2B4 mAb unsuitable for such exper-
iments. Finally, recent observations that there are differ-
ences in phenotype between CD48- (40) and CD2-defi-
cient mice (41, 42) can now be investigated with reference
to the existence of an alternative ligand for CD48.
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